f.okwuosa99/100
Cold chain intact. Phase-change pack solid at arrival, day 9. Submitted to the index in full.
ERP — Shanghai ERP Biotechnology Co., Ltd.
Shanghai, CN · established 2018. The index holds 205 assay reports across 38 batches and 26 compounds, contributed by 6 laboratories. Every figure below is computed from those records and from nothing else.
Where ERP sells
Shanghai ERP Biotechnology Co., Ltd. sells from its own storefront. The link is marked nofollow and sponsored: it exists so the figures on this scorecard can be read against what the supplier itself publishes. The index is paid nothing for it and a link is not an assessment.
Visit ERP at erpbiotechnology.com →
Every figure above describes lots the index has seen. It says nothing about the lot you are offered, and the only check that does is the one on the certificate against the vial.
Block 1
Identification
Business facts, held constant across the index and not derived from the data. The index sells nothing and takes no supplier payment for placement; the storefront link below is marked nofollow and sponsored so a record can be checked against the seller, and is not a recommendation.
- Legal name
- Shanghai ERP Biotechnology Co., Ltd.
- Short code in this index
- ERP
- Also known as
- ERP · ERP Biotech · Shanghai ERP Biotechnology
- Domain
- erpbiotechnology.com →
- City
- Shanghai
- Region
- Shanghai
- Country
- CN
- Established
- 2018
- First record in index
- 13 Apr 2024
- Most recent record
- 04 Oct 2026
Block 1b
Dispatch and regional stock
Counted from the chain-of-custody line on this supplier's own records, which names the route each vial travelled to the laboratory, and from the on-record reviews below. The index has no sight of any supplier's warehouse network and publishes none.
Domestic-warehouse route
14.1%
n=205
Retail, shipped to the buyer
71.2%
n=205
Direct to the laboratory
5.9%
n=205
Median courier leg, direct despatch
10d
n=12
| Route to the laboratory | Records | Share |
|---|---|---|
| Domestic warehouse despatch | 29 | 14.1% |
| Retail purchase, shipped to the buyer | 122 | 59.5% |
| Retail purchase via a third-party forwarder | 24 | 11.7% |
| Supplier despatch direct to the laboratory | 12 | 5.9% |
| Laboratory retained-sample archive | 18 | 8.8% |
Every record here carries a chain-of-custody line and that line names the route the vial travelled. Of the 205 ERP records the index holds, 29 reached the contributing laboratory from a domestic warehouse rather than as a cross-border consignment, covering 16 of the 26 compounds ERP is represented by here — Ipamorelin, BPC-157, GHK-Cu, Semax, Oxytocin, TB-500 and 10 further compounds. Those are the ERP lines this index has actually seen arrive from regional stock, and they are a count of consignments rather than a stock listing: a line missing from them may simply never have been submitted for assay.
One contributor on the record below documents ERP stock held in Poland, with a transit of 2 working days against a quoted 2. Poland is the only regional stock location named anywhere in ERP's record here, and one consignment described by one buyer is exactly that. It is not a warehouse list and the index has not verified it.
The index measures nothing about lead time — it assays material, it does not buy it. What it has is ERP's own reviewers: 4 of the 26 on-record reviews state a quoted window and what happened against it. Where ERP despatched a sample direct to a laboratory, the courier leg ran a median 10 days across 12 such consignments — that is a transit time the index can see, and it is not the same thing as a lead time. The reviews are reproduced in full in Block 11.
Block 2
Headline statistics
Each figure carries the n it was computed from. The n= badge next to a statistic is the number of records it was computed from. Below n=8 the badge is amber. Below n=3 the statistic is suppressed and the individual values are shown instead.
Median purity
99.03%
n=204
Interquartile range
0.72pp
n=204
10th percentile
98.28%
n=204
Pass rate vs index spec
94.1%
n=204
Median recovery vs claim
96.2%
n=127
Median water
4.15%
n=205
Median |mass error|
2.3ppm
n=172
Records carrying a flag
35.1%
n=205
Block 3
Reproducibility across independent tests of one lot
Where the same physical lot was assayed more than once, the spread between those results is a property of the material and the fill, not of the market. It is the rarest and most informative statistic on this page, and it exists only for lots someone tested twice.
Median within-batch spread
0.52pp
n=25
Index median spread
0.67pp
n=28
Lots tested 3+ times
25
n=38
Across the 25 ERP lots in the index with three or more independent assays, the median spread between the highest and lowest purity result on one lot is 0.52 pp. Interpreting that number requires the laboratory repeatability figures: the best contributing laboratory here repeats to 0.16 pp and the worst to 0.34 pp, so a within-lot spread under about 0.5 pp is indistinguishable from measurement noise and a spread above 1 pp is a statement about the material.
Block 4
Supplier certificate against independent measurement
The supplier's own COA purity figure for a lot, minus the median of the index's independent observations of the same physical lot. Positive means the certificate reads higher than the measurement. Rule AX-R05 fires above 1.5 pp.
Median COA divergence
+0.08pp
n=37
Index median divergence
+0.06pp
n=28
Divergences in the supplier's favour
57%
n=37
Divergences beyond 1 pp
0%
n=37
Block 5
Provenance — where the tested material came from
Supplier-supplied samples are weaker evidence than independently purchased ones, because the supplier chose the vial. The index measures the size of that effect rather than assuming it.
Buyer-sourced median
99.02%
n=174
Supplier-supplied median
99.37%
n=12
Supplier-supplied share of records
5.9%
n=205
Block 6
Documentation completeness
The score is not an opinion about paperwork. Each component is the share of ERP batches in the index whose certificate carries that field, weighted as set out on the scoring rubric.
Documentation score
80/100
n=38
Index median score
85/100
n=28
| Certificate field | Batches carrying it | Rubric weight | |
|---|---|---|---|
| Purity figure stated | 100% | 25 points | |
| Analytical method stated (column, gradient, wavelength) | 71% | 25 points | |
| Peptide content stated | 45% | 20 points | |
| Endotoxin stated | 29% | 15 points | |
| Named impurities rather than a total | 46% | 15 points |
Block 7
Coverage by compound
The delta column is this supplier's median minus the index-wide median for the same compound, which is the only comparison worth making: comparing a supplier's aggregate against another supplier's aggregate compares their product mixes as much as their process control.
| Compound | Class | Reports | Median % | Index median % | Δ (pp) | Index spec | Pass % |
|---|---|---|---|---|---|---|---|
| Tirzepatide | Incretin | 26 | 98.40 | 98.55 | -0.15 | 97.0 | 100 |
| Ipamorelin | Growth-hormone | 25 | 99.41 | 99.47 | -0.06 | 99.0 | 80 |
| TB-500 | Tissue-repair | 23 | 99.28 | 99.53 | -0.25 | 98.5 | 100 |
| BPC-157 | Tissue-repair | 19 | 99.33 | 99.16 | +0.17 | 98.0 | 100 |
| MOTS-c | Metabolic | 12 | 99.01 | 99.13 | -0.12 | 98.0 | 100 |
| GHK-Cu | Tissue-repair | 10 | 98.65 | 98.56 | +0.09 | 97.0 | 100 |
| CJC-1295 (no DAC) | Growth-hormone | 10 | 98.86 | 99.09 | -0.23 | 98.0 | 100 |
| CJC-1295 with DAC | Growth-hormone | 9 | 99.11 | 98.95 | +0.16 | 97.5 | 100 |
| GHRP-6 | Growth-hormone | 9 | 98.83 | 99.54 | -0.71 | 99.0 | 22 |
| Gonadorelin | Hypothalamic | 9 | 99.80 | 99.12 | +0.68 | 98.5 | 100 |
| Semaglutide | Incretin | 8 | 99.36 | 98.89 | +0.47 | 97.0 | 100 |
| Kisspeptin-10 | Melanocortin-receptor | 7 n=7 | 99.07 | 99.28 | -0.21 | 98.5 | 100 |
| PEG-MGF | Growth-hormone | 6 n=6 | 98.22 | 97.75 | +0.47 | 92.0 | 100 |
| Humanin (HNG) | Metabolic | 6 n=6 | 98.73 | 99.12 | -0.39 | 97.5 | 100 |
| Semax | Neuroactive | 5 n=5 | 99.46 | 99.46 | 0.00 | 98.5 | 100 |
| Oxytocin | Hypothalamic | 5 n=5 | 99.09 | 99.81 | -0.72 | 98.5 | 100 |
| Mazdutide | Incretin | 4 n=4 | 97.77 | 98.14 | -0.38 | 96.5 | 100 |
| Survodutide | Incretin | 2 n=2 | n<3 | 98.38 | — | 96.5 | 100 |
| Glucagon | Incretin | 2 n=2 | n<3 | 99.20 | — | 98.0 | 100 |
| MGF | Growth-hormone | 2 n=2 | n<3 | 99.29 | — | 97.5 | 100 |
| Tesamorelin | Growth-hormone | 1 n=1 | n<3 | 98.29 | — | 97.0 | 100 |
| Liraglutide | Incretin | 1 n=1 | n<3 | 99.00 | — | 97.5 | 100 |
| Retatrutide | Incretin | 1 n=1 | n<3 | 98.37 | — | 96.5 | 100 |
| Pemvidutide | Incretin | 1 n=1 | n<3 | 98.25 | — | 96.0 | 100 |
| Follistatin-344 | Growth-hormone | 1 n=1 | n<3 | — | — | 98.0 | — |
| NAD+ | Non-peptide | 1 n=1 | n<3 | 99.28 | — | 97.0 | 100 |
Full per-compound breakdown with distributions and caveats →
Block 8
Quarterly trend
Submission volume is not market share and a quarterly median is not a trend unless the compound mix held still. Both caveats apply to every row below.
Median purity by quarter
Quarters with fewer than two purity records are gaps in the line rather than zeroes.
Coverage growth
Records added per quarter. Growth here is index coverage, not supplier volume.
| Quarter | Batches | Reports | Median purity | Range | Flagged |
|---|---|---|---|---|---|
| 2024-Q1 | 0 | 0 | n<3 | — | 0 |
| 2024-Q2 | 3 | 26 | 98.92 | 98.24–99.76 | 4 |
| 2024-Q3 | 6 | 39 | 99.00 | 97.62–99.93 | 14 |
| 2024-Q4 | 1 | 1 | n<3 | — | 0 |
| 2025-Q1 | 4 | 8 | 99.66 | 98.51–99.93 | 1 |
| 2025-Q2 | 2 | 7 | 99.02 | 98.61–99.11 | 3 |
| 2025-Q3 | 6 | 41 | 99.05 | 98.51–99.68 | 10 |
| 2025-Q4 | 6 | 43 | 99.24 | 98.67–99.93 | 19 |
| 2026-Q1 | 4 | 19 | 98.68 | 97.73–99.93 | 6 |
| 2026-Q2 | 4 | 18 | 98.59 | 97.65–99.25 | 14 |
| 2026-Q3 | 2 | 3 | 98.38 | 98.24–99.02 | 1 |
Block 9
Which laboratory produced these numbers
Laboratories disagree with each other by a measured amount. A supplier tested mostly by one laboratory carries that laboratory's offset in its aggregate, and the adjusted column removes it.
| Laboratory | Reports | Median purity | Lab bias (pp) | Bias-adjusted |
|---|---|---|---|---|
| Janoshik | 89 | 99.06 | +0.00 | 99.06 |
| PeptideMeter | 36 | 98.88 | -0.05 | 98.93 |
| Medutest | 24 | 99.09 | +0.08 | 99.01 |
| VendorInvestigate | 22 | 98.87 | -0.11 | 98.98 |
| Nordanalyt | 18 | 99.25 | +0.02 | 99.23 |
| Kestrel | 16 | 99.24 | +0.24 | 99.00 |
Bias figures are estimated from paired same-lot comparisons and are published with their confidence intervals on inter-lab agreement.
Block 10
What this data does and does not show
Block 11
On-the-record reviews 26
Reviews are signed statements from index contributors about their own testing of this supplier's material. They are opinions attached to evidence, and they are not used in any statistic on this page.
93.0/ 100894 ratings across the index network
le.haddad100/100
Quote correct at first issue: vial size, quantity, unit price and lead time. Documentation complete at first issue.
d.batista97/100
Counter-ion identity and content answered quantitatively, one working day. Documentation practice, not a single purity figure, is the substance here.
i.trevino98/100
Direct-supply material 97.9%. Intermediary vial, same nominal description, 98.0%. Tracking record corresponded to consignment position at every hop.
ca.espinoza95/100
Residual-solvent screen included unrequested. Catalogue availability matched the published catalogue.
i.zielinski96/100
Line quoted that three comparable suppliers declined to quote. Material returned within specification. Gradient and column chemistry stated. Submitted to the index in full.
z.moreau98/100
Declared figure not adjusted upward between certificate and commercial documentation.
s.trevino99/100
Labelling printed, lot and date legible on every unit examined. Contributor declares no interest beyond the transaction.
h.stanescu96/100
Consistency: 12 lots, purity band under 1.0 points wide. Further submissions on later lots would improve coverage.
d.guerrero97/100
Transit 2 days from stock held in Poland against a quoted 2. Customs documentation correct at first presentation. Tracking record corresponded to consignment position at every hop. n=1, declared as n=1.
a.sobczak100/100
Cold chain held. Phase-change pack solid at arrival on day 3, cake intact and unshifted. All other particulars in order.
b.vukovic98/100
Release signed and dated, named individual. Signature and release date present.
e.onwuka97/100
Lot ERP-24-769 submitted to Janoshik. Declared 97.8%, reported 97.8%. Delta inside method repeatability. Research use. Not approved for human administration.
an.pereira96/100
Supplementary certificate for a lot released 6 months earlier retrieved from supplier records on request.
r.sjoberg95/100
Repeat determination at 14 months: 97.8%. Original: 97.8%. No drift detected in this sample.
m.hovland100/100
Peptide content reported separately from chromatographic purity on every certificate held. Nine lots, no exception.
k.petrescu98/100
Certificate carries the method and the wavelength it was run at. Complete against the index minimum data set at first issue.
k.lundgren97/100
Fill uniformity: 12 units weighed against declared fill, all within 2%. Record covers the lots named. Not generalised.
an.aguirre96/100
Related-substances table itemised by impurity with assigned retention times. Not aggregated. Figures as reported by the named service. Not reproduced by the index.
b.vogel95/100
Packing: a tamper strip that had to be cut rather than peeled. No further comment.
n.brandt97/100
Batch record supplied in full on request, attached rather than summarised. Subsequent orders placed with the same supplier.
m.serrano100/100
Quote matched the order form line for line and the price held to invoice. No further comment.
r.karlsen95/100
Purity by RP-HPLC, wavelength stated, stability-indicating method named. Determination is reproducible from the certificate alone. Catalogue availability matched the published catalogue. Further submissions on later lots would improve coverage.
me.agyeman96/100
Orthogonal identity present: mass spectrometry alongside the chromatographic determination. Signature and release date present.
h.hartmann98/100
Peptide content reported separately from chromatographic purity across all 6 certificates held. Declared and independent figures differ by less than repeatability.
v.pires99/100
Storage condition for the stability statement stated on the certificate. PeptideMeter report held on file, figures match published. No adverse observation.
Block 12
Most recent records
Block 13
Contributor annotations on ERP records 359
Annotations are this index's only discussion surface: signed technical comments attached to a specific record by a named contributor. They are not moderated for agreement with the index's own arithmetic. The most recent on ERP material are below, each linked to the record it sits on.
Base peak lands where the charge-state arithmetic says it should for a species of this mass. That agreement is a check on the deconvolution rather than on the material, and it passes.
Instrument class is on the record, which is what allows -2.2 ppm to be read at its proper weight. The index distinguishes "confirmed" from "consistent with" precisely on this field.
Adduct bookkeeping on this one is tidy. The sodium series is present at the expected intensity ratio and has not been counted as an impurity, which happens more often than it should.
Deconvolution over a full charge-state envelope with an internal calibrant is what makes +5.3 ppm mean something. All three conditions look satisfied on this record.
Mass, retention and impurity profile all agree on this record. Three independent constraints pointing the same way is the strongest identity evidence the index publishes.
Identity confirmed and purity at 98.88 %. The two answer different questions — what it is, and how much else is in it — and a record carrying both is the version worth citing.
A rounded purity and an unrounded impurity total on the same certificate will not sum to 100 exactly, and that is a rounding artefact rather than the arithmetic failure rule AX-R02 looks for. The slack allowance exists for it.
The dataset records the declared purity exactly as printed, including its precision. Anyone testing digit preference over the CSV is testing the certificates rather than the index's handling of them.
Every annotation the index holds on ERP material sits on its own record; the full set is reachable from the record listing and from each contributor's page. To read them against what ERP itself publishes, open erpbiotechnology.com → alongside.
Block 14
Where to buy ERP
Shanghai ERP Biotechnology Co., Ltd. sells direct from erpbiotechnology.com. Everything on this page describes lots the index has already seen; the certificate that matters is the one that arrives with the vial you order, and the lot code on it should match the vial. Ask for the lot-specific document rather than the batch-level summary, and ask for the integration report if you intend to reconcile the figure yourself.
Go to the ERP store at erpbiotechnology.com →
Marked nofollow and sponsored. The index is paid nothing for it, takes no commission, and a link is not an assessment. Research compounds. Not medical advice. Nothing on this site is a safety assessment and nothing on it is approved for human use.